retatrutide clinical trial results obesity Safety, Side Effects & Provider Use retatrutide clinical trial results 2024

However, the structured dose titration protocols used in trials are absent in self-administration scenarios, significantly increasing the likelihood and severity of these reactions

Adapted from KDIGO 2022 [81]

In the UK, approximately 28% of adults live with obesity, leading many to seek alternatives to injections, but current patch technology cant effectively deliver peptide hormones, like GLP-1, through the skin

These complications are asymptomatic in the early stages (meaning you dont have symptoms), so theyre harder to detect, and healthcare providers often miss them

Glapp follows the same security-first principles commonly applied in HIPAA and ISO 27001 compliant health products, with privacy and data protection considered from day one